These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 21346752)

  • 1. Coding of DNA samples and data in the pharmaceutical industry: current practices and future directions--perspective of the I-PWG.
    Franc MA; Cohen N; Warner AW; Shaw PM; Groenen P; Snapir A;
    Clin Pharmacol Ther; 2011 Apr; 89(4):537-45. PubMed ID: 21346752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Challenges in obtaining adequate genetic sample sets in clinical trials: the perspective of the industry pharmacogenomics working group.
    Warner AW; Bhathena A; Gilardi S; Mohr D; Leong D; Bienfait KL; Sarang J; Duprey S; Franc MA; Nelsen A; Snapir A
    Clin Pharmacol Ther; 2011 Apr; 89(4):529-36. PubMed ID: 21346757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current practices for DNA sample collection and storage in the pharmaceutical industry, and potential areas for harmonization: perspective of the I-PWG.
    Franc MA; Warner AW; Cohen N; Shaw PM; Groenen P; Snapir A
    Clin Pharmacol Ther; 2011 Apr; 89(4):546-53. PubMed ID: 21368755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Global requirements for DNA sample collections: results of a survey of 204 ethics committees in 40 countries.
    Ricci DS; Broderick ED; Tchelet A; Hong F; Mayevsky S; Mohr DM; Schaffer ME; Warner AW; Hakkulinen P; Snapir A
    Clin Pharmacol Ther; 2011 Apr; 89(4):554-61. PubMed ID: 21346753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PhRMA survey of pharmacogenomic and pharmacodynamic evaluations: what next?
    Grecco N; Cohen N; Warner AW; Lopez-Correa C; Truter SL; Snapir A; Piccoli SP; Wang D; Westelinck A; Hinman L; Franc MA;
    Clin Pharmacol Ther; 2012 Jun; 91(6):1035-43. PubMed ID: 22534869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of ADME pharmacogenomics in early clinical trials: perspective of the Industry Pharmacogenomics Working Group (I-PWG).
    Tremaine L; Brian W; DelMonte T; Francke S; Groenen P; Johnson K; Li L; Pearson K; Marshall JC
    Pharmacogenomics; 2015 Dec; 16(18):2055-67. PubMed ID: 26616152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Designing pharmacogenetic projects in industry: practical design perspectives from the Industry Pharmacogenomics Working Group.
    Bromley CM; Close S; Cohen N; Favis R; Fijal B; Gheyas F; Liu W; Lopez-Correa C; Prokop A; Singer JB; Snapir A; Tchelet A; Wang D; Goldstaub D;
    Pharmacogenomics J; 2009 Feb; 9(1):14-22. PubMed ID: 18794908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Global gene mining and the pharmaceutical industry.
    Knudsen LE
    Toxicol Appl Pharmacol; 2005 Sep; 207(2 Suppl):679-83. PubMed ID: 15979678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Family consent and the pursuit of better medicines through genetic research.
    Renegar G; Rieser P; Manasco P
    J Contin Educ Health Prof; 2001; 21(4):265-70. PubMed ID: 11803771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elements of informed consent for pharmacogenetic research; perspective of the pharmacogenetics working group.
    Anderson DC; Gomez-Mancilla B; Spear BB; Barnes DM; Cheeseman K; Shaw PM; Friedman J; McCarthy A; Brazell C; Ray SC; McHale D; Hashimoto L; Sandbrink R; Watson ML; Salerno RA; Cohen N; Lister CE;
    Pharmacogenomics J; 2002; 2(5):284-92. PubMed ID: 12439734
    [No Abstract]   [Full Text] [Related]  

  • 11. The value of banked samples for oncology drug discovery and development.
    Shaw PM; Patterson SD
    J Natl Cancer Inst Monogr; 2011; 2011(42):46-9. PubMed ID: 21672897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetics and pharmacogenomics in drug development and regulatory decision making: report of the first FDA-PWG-PhRMA-DruSafe Workshop.
    Lesko LJ; Salerno RA; Spear BB; Anderson DC; Anderson T; Brazell C; Collins J; Dorner A; Essayan D; Gomez-Mancilla B; Hackett J; Huang SM; Ide S; Killinger J; Leighton J; Mansfield E; Meyer R; Ryan SG; Schmith V; Shaw P; Sistare F; Watson M; Worobec A
    J Clin Pharmacol; 2003 Apr; 43(4):342-58. PubMed ID: 12723455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetics: the bioethical problem of DNA investment banking.
    Corrigan OP; Williams-Jones B
    Stud Hist Philos Biol Biomed Sci; 2006 Sep; 37(3):550-65. PubMed ID: 16980194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment by human research ethics committees of potential conflicts of interest arising from pharmaceutical sponsorship of clinical research.
    Newcombe JP; Kerridge IH
    Intern Med J; 2007 Jan; 37(1):12-7. PubMed ID: 17199839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacometrics 2020.
    Gobburu JV
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):151S-157S. PubMed ID: 20881229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An industry survey on current practices in the design and analysis of active control studies.
    Chuang-Stein C; Sanders C; Snapinn S
    J Biopharm Stat; 2004 May; 14(2):349-58. PubMed ID: 15206532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The drug diagnostic co-development concept paper: commentary from the 3rd FDA-DIA-PWG-PhRMA-BIO Pharmacogenomics Workshop.
    Hinman LM; Huang SM; Hackett J; Koch WH; Love PY; Pennello G; Torres-Cabassa A; Webster C
    Pharmacogenomics J; 2006; 6(6):375-80. PubMed ID: 16652120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2397-406. PubMed ID: 12692171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ethical, social and legal implications of pharmacogenomics: a critical review.
    Moldrup C
    Community Genet; 2001; 4(4):204-14. PubMed ID: 12751484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.